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Randomised, double blind, placebo controlled crossover
trial of sustained release morphine for the management
of refractory dyspnoea
Amy P Abernethy, David C Currow, Peter Frith, Belinda S Fazekas, Annie McHugh, Chuong Bui
Abstract
Objective To determine the efficacy of oral morphine
in relieving the sensation of breathlessness in patients
in whom the underlying aetiology is maximally
treated.
Design Randomised, double blind, placebo controlled
crossover study.
Setting Four outpatient clinics at a hospital in South
Australia.
Participants 48 participants who had not previously
been treated with opioids (mean age 76, SD 5) with
predominantly chronic obstructive pulmonary disease
(42, 88%) were randomised to four days of 20 mg oral
morphine with sustained release followed by four days
of identically formulated placebo, or vice versa.
Laxatives were provided as needed.
Main outcome measures Dyspnoea in the morning
and evening as shown on a 100 mm visual analogue
scale, quality of sleep, wellbeing, performance on
physical exertion, and side effects as measured at the
end of the four day treatment period.
Results 38 participants completed the study; three
withdrew because of definite and two because of
possible side effects of morphine (nausea, vomiting,
and sedation). Participants reported significantly
different dyspnoea scores when treated with
morphine: an improvement of 6.6 mm (95%
confidence interval 1.6 mm to 11.6 mm) in the
morning and of 9.5 mm (3.0 mm to 16.1 mm) in the
evening (P = 0.011 and P = 0.006, respectively). During
the period in which they were taking morphine
participants also reported better sleep (P = 0.039).
More participants reported distressing constipation
while taking morphine (9 v 1, P = 0.021) in spite of
using laxatives. All other side effects were not
significantly worse with morphine, although the study
was not powered to address side effects.
Conclusions Sustained release, oral morphine at low
dosage provides significant symptomatic
improvement in refractory dyspnoea in the
community setting.
Introduction
Breathlessness is a source of distress for 50-70% of
patients requiring palliative care.1 A complex physio-
logical and psychological sensation, its causes are often
multifactorial, including the underlying disease,
cachexia, and deconditioning.1 2 As disease progresses
dyspnoea occurs more frequently and at rest.1 3
Depression, panic, anxiety, and insomnia can all result
from the symptom and exacerbate it.4 5 Family and car-
ers feel helpless as they face their distressed relative.
Despite optimal medical management many
people are still breathless.2 Non-pharmacological
approaches such as cognitive behaviour therapy,
relaxation, breathing control, and cool air flowing from
a fan directed at the face have provided some benefit.6
Respiratory rehabilitation is generally aimed at
improving level of function rather than definitive
symptomatic benefit.7
Some clinicians acknowledge that opioids have a
role in the management of intractable dyspnoea.8–10 In
Australia, consensus guidelines from the Therapeutic
Guidelines Group in Palliative Care conclude that
opioids contribute to the management of refractory
dyspnoea.10 By contrast, the consensus summary of the
Global Initiative on Chronic Obstructive Lung Disease
(GOLD) of the National Heart, Lung, and Blood Insti-
tute of the US National Institutes of Health and the
World Health Organization states that opioids are
contraindicated in the management of dyspnoea in
chronic obstructive pulmonary disease.11 Concerns
about respiratory depression and hypercapnia are
cited.
The lack of consensus is understandable since high
quality studies evaluating the role of opioids in the man-
agement of dyspnoea have been lacking. A meta-
analysis of the double blind, randomised, placebo
controlled studies to date indicates that oral or
parenteral opioids are beneficial, but this conclusion is
based on small trials using different opioids, methods,
and outcomes.9 Many of the studies thus far have
focused on trying to establish whether opioids can
improve function in the setting of dyspnoea. For
patients, the relief of the sensation of dyspnoea is
critical.8 12
We evaluated the ability of opioids to relieve the
sensation of breathlessness when the underlying
aetiology has been maximally treated. We chose oral,
sustained release morphine to reflect practical clinical
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care for outpatients. Our hypothesis was that
morphine would be superior to placebo.
Methods
Participants
We recruited participants during April-November
2001, from the outpatient clinics for respiratory,
cardiac, general, and palliative medicine at the
Repatriation General Hospital in South Australia. Par-
ticipants needed to be opioid naive (not formerly
treated with long term opioids) adults with dyspnoea at
rest in spite of receiving optimal treatment of reversible
factors. Optimal treatment was considered to be in
place if a specialist for respiratory, cardiac, or palliative
care had reviewed the clinical case, examined the
patient, and treated all identified reversible causes of
the dyspnoea. Other inclusion criteria were serum
concentration of creatinine within twice the normal
range, stable needs for oxygen and medication, and the
ability to fill out diary cards. Exclusion criteria were
recent use of opioids, confusion, obtundation, adverse
reactions to opioids, and history of substance misuse.
Protocol
Baseline assessment on day 0 included recording the
participant’s demographic characteristics, medical his-
tory, physical examination, vital signs, medications, and
oxygen requirements. We measured performance
status by using the categorical scale of the Eastern
Cooperative Oncology Group (ECOG), where 0 is
“fully active” and 4 is “completely disabled.”13
This was an eight day, randomised, double blind,
crossover study. Participants received 20 mg oral mor-
phine sulphate with sustained release (Kapanol, Glaxo
Wellcome Australia) in the morning for four days, fol-
lowed by four days of identically formulated placebo,
or vice versa. They also received open label docusate
sodium (50 mg) plus senna (8 mg) capsules (Coloxyl
with Senna, Sigma) and were advised to take up to four
daily as needed.
Since the active medication was a sustained release
preparation we defined steady state as five times the
period from administration to maximum concentra-
tion. For the product used the time to maximum con-
centration was nine to 12 hours. Steady state was
between 45 and 60 hours. Outcome measures on days
4 and 8 provided steady state data. The design did not
include a washout period. We defined the analysis a
priori to compare the results at the end of each period
rather than the differences between the end of the
period and baseline for the period.14 15
Participants filled out diary cards each morning
and evening on days 1-8 to ensure consistent
reporting. Study nurses visited on days 4 and 8 and tel-
ephoned on days 2 and 6 to answer questions and
assess safety. Medication bottles were collected at the
end of the study to document compliance.
The primary outcome variable was the sensation of
dyspnoea as measured on a visual analogue scale in the
evening on the final day of the period.16 Anchors were
“no breathlessness” at 0 mm and “worst possible
breathlessness” at 100 mm. Other variables included
morning dyspnoea on the scale, exercise tolerance
measured on the modified scale of the Medical
Research Council of Great Britain, respiratory rate,
blood pressure, heart rate, oxygen saturation, distur-
bance of sleep by breathlessness, and four or five point
categorical scales for nausea and vomiting, constipa-
tion, confusion, somnolence, appetite, and overall well-
being.17 Study nurses used a categorical scale to
evaluate any sedation.
Assignment and blinding
Randomisation and blinding were coordinated
through the hospital pharmacy’s centralised service.
This included computerised generation of the alloca-
tion sequence in random permuted blocks and blinded
disbursement of medication. After review of eligibility
and consent, participants were randomised to four
days of taking active drug followed by four days of tak-
ing placebo, or vice versa. The placebo medication was
identical in appearance and taste to the active
medication; the bottle indicated which medication to
take each day. Participants were unblinded to the inves-
tigators for serious adverse events only.
Sample size
We calculated the sample size by using previous
reports of improvement in dyspnoea with morphine
and local expectations for data variability in this cross-
over study; the predicted standard deviation of the
visual analogue scale was 16 mm.16 We estimated that
48 participants would provide 80% power to detect a
10 mm difference in the scale, with an  of 0.05, allow-
ing for a 20% dropout rate.
Statistical analysis
We prespecified all analyses on an intention to treat
basis. Data were double entered, and we used SPSS for
Windows, version 11.0, for our statistical analysis. We
used descriptive statistics to summarise the popula-
tion’s characteristics, breathlessness, and side effects.
We evaluated sequence and period effects before
testing for any treatment effect; if either was identified
we did not conduct an analysis of the treatment.14 18 We
used Student’s t test, 2 test, and Fisher’s exact test to
evaluate sequence effects and the paired samples t test
and McNemar’s test to evaluate period effects. We
approached analysis of the treatment effect in this two
period, crossover trial by looking at the differences in
the final result for each period.14 Since data on the
visual analogue scale were acceptably normally distrib-
uted we used the paired samples t test to test relations
for this continuous variable. We used McNemar’s test
for relations between categorical variables. We
reported two tailed P values and assumed statistical
significance if P < 0.05. We conducted sensitivity analy-
sis by modelling worsening dyspnoea from baseline for
patients who had withdrawn, by increasing end period
morphine scores on the visual analogue scale by
5-30%.
Results
Flow of participants and follow up
Figure 1 shows the progress of participants through
the study. Ten participants withdrew; five during the
morphine period and five during the placebo period.
Thirty eight participants completed the study, and
compliance with the intervention and follow up were
complete for all participants.
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Participants were mainly elderly men with chronic
obstructive pulmonary disease who were receiving
supplemental oxygen (table 1). Functional status was
generally poor, with 71% (34) unable to carry out any
work activities (ECOG ≥ 2). Baseline characteristics
were similar for both groups.
Sequence and period analysis
A sequence effect is noted when a difference occurs in
response to treatment in period 1 compared with
period 2, most commonly seen because an effect from
active treatment is carried over into the outcome
measurements of the next period. A period effect is
noted when the underlying condition or ability to
respond to treatment changes from one period to the
next. In a crossover design, responses to treatment are
suspect if any sequence or period effects are noted. In
this study, we identified no notable sequence or period
effects.
Treatment analysis
Dyspnoea control
At the end of the four day period, sustained release
morphine was superior to placebo in diminishing dys-
pnoea (table 2). In the evening morphine resulted in an
improvement of 9.5 mm (SD 19, 95% confidence inter-
val 3.0 mm to 16.1 mm, P = 0.006) in the reported
dyspnoea score on the visual analogue scale. In the
morning morphine resulted in an improvement of 6.6
mm (SD 15, 1.6 mm to 11.6 mm, P = 0.011).
Significantly fewer participants receiving morphine
reported that their sleep was disturbed by breathless-
ness (1 v 8, P = 0.039; table 3). Exertional performance
and overall sense of wellbeing were not significantly
different (data not presented).
Side effects
The respiratory rate was similar for patients receiving
morphine (mean 20, SD 5) and placebo (mean 21, SD 4;
P = 0.143). No episodes of severe sedation or obtunda-
tion were recorded. Side effects potentially attributable
to morphine were quantified. Categorical responses
were collapsed into categories for “no” or “mild” distress
and “moderate” or “severe” distress. Morphine caused
more distressing constipation than placebo (9 v 1,
P = 0.021; table 44). Neither treatment caused signifi-
cantly more distressing vomiting, confusion, sedation, or
suppression of appetite (data not presented).
As the occurrence of a side effect may have
changed over the treatment period, the frequency of
symptoms throughout the treatment period was
reviewed. The morphine group consistently reported
more constipation across the period. When morphine
was administered first, the carry over of constipation
into the placebo period was resolved by the end of the
placebo period (figure 2). Other symptoms were
relatively stable across both periods; the results are not
shown here.
Participants’ withdrawals
Ten participants withdrew from the study; three
because of morphine side effects, two because of
Screened patients (n=104)
Randomised (n=48)
Morphine (n=24)
Withdrawals (n=4)
Eligible participants (n=87)
Consent to participate (n=48)
Decline consent (n=23)
Cannot participate because of illness 
  or other reason (n=16)
Total completed trial (n=38)
Total withdrawals (n=10)
Withdrawals receiving morphine (n=5)
Withdrawals receiving placebo (n=5)
Placebo (n=24)
Withdrawals (n=3)
Placebo (n=20)
Withdrawals (n=2)
Morphine (n=21)
Withdrawals (n=1)
Completed trial (n=18) Completed trial (n=20)
Flow of participants through the trial
Table 1 Baseline characteristics of participants (n=48). Values are numbers
(percentages) unless otherwise indicated
Characteristic
Mean (SD) age in years 76 (5)
Male sex 35 (73)
Dominant aetiology of dyspnoea:
Chronic obstructive pulmonary disease 42 (88)
Cancer 3 (6)
Motor neurone disease 1 (2)
Restrictive lung disease 2 (4)
Receiving supplemental oxygen 34 (71)
Mean (SD) litres per minute 1.4 (1.2)
ECOG performance status score:
0=fully active 0 (0)
1=restricted in strenuous activity only 14 (29)
2=unable to work; up and about more than 50% of waking hours 20 (42)
3=confined to bed or chair more than 50% of waking hours 13 (27)
4=completely disabled; totally confined to bed or chair 1 (2)
Respiratory rate in breaths per minute (SD) 20 (4)
Mean (SD) haemoglobin (mmol/l) 8.4 (1.1)
Mean (SD) morning dyspnoea score (VAS) 43 (26)
Mean (SD) morning dyspnoea score (VAS) range 2-92
ECOG=Eastern Cooperative Oncology Group.
VAS=visual analogue score.
Table 2 Effect of morphine versus placebo on the sensation of dyspnoea at the end of the treatment period. End period values for
morphine and placebo are means (SD). In this paired t test the differences in the same patient between morphine and placebo are
presented as absolute values of the means (SD); 95% confidence intervals are also absolute values
Dyspnoea*
Morphine
(n=38)
Placebo
(n=38)
Mean improvement in dyspnoea scores
on morphine compared with placebo
95% CI of the mean
improvement
P value
(paired t test)
Morning 40.1 (24) 47.7 (26) 6.6 (15) 1.6 to 11.6 0.011
Evening 40.3 (23) 49.9 (24) 9.5 (19) 3.0 to 16.1 0.006
*Dyspnoea is measured on a 100 mm visual analogue scale (VAS), with zero as “no breathlessness” and 100 as “worst possible breathlessness.”
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potential morphine effects, and five for reasons
unlikely to be related to morphine (table 5). All of those
who withdrew because of side effects of morphine
reported that the symptom was causing them “moder-
ate” or “severe” distress. Notably, one participant’s dys-
pnoea was so improved with the first treatment
(morphine) that the participant withdrew at crossover.
Sensitivity analysis
A conservative sensitivity analysis model assumed that
all participants who withdrew did so because of
problems with morphine. We included baseline scores
on the visual analogue scale for the 10 withdrawn par-
ticipants in the study dataset and then increased the
scores for the end period on morphine systematically
to model worsening dyspnoea. All participants who
withdrew could have had at least a 10% worsening of
their morning scores for dyspnoea or a 25% worsening
of their evening scores, and the results of this study
would still show a statistically significant improvement
with morphine.
Discussion
Oral, sustained release morphine can provide added
relief to patients who have intractable breathlessness
despite maximal treatment of the underlying causes of
dyspnoea. In this adequately powered, randomised
controlled trial, morphine provided a 7-10 mm
improvement in the visual analogue scale for
dyspnoea—results with both clinical and statistical
significance. These results were corroborated by
participants’ reports of much better sleep during the
morphine period. Sensitivity analysis showed that
morphine still provided clinical benefit to the study
population even if the modelled participants who
withdrew experienced 25% worsening of their
dyspnoea. Further, the results showed the same magni-
tude of improvement as seen in the pooled results of
other trials (8 mm on the visual analogue scale).9
The results of this study are applicable to many
outpatient settings in general practice, palliative care,
and respiratory care. The study population of elderly,
poorly functioning people predominantly with chronic
obstructive pulmonary disease represents patients we
encounter often, for whom few symptomatic options
are available. The criteria used to identify participants
were simple and as broad as possible. Patients needed
only to be suffering from the symptom of refractory
breathlessness. We specifically avoided invasive proce-
dures such as measuring arterial blood gases or
pulmonary function to identify eligible candidates as
this would not be generalisable or ethical for many
outpatient and palliative care settings.
Oral, long acting morphine was chosen for its con-
venience and continuous action. The sustained release
morphine product used can be given once daily;
evidence for its efficacy as a 24 hour medication was
provided by the dramatic improvements in the evening
dyspnoea scores. A small background dose of opioid
may be better tolerated than the peaks and troughs of
immediate release formulations.19
Although the results are significant and generalis-
able, clinicians should prescribe morphine for the con-
trol of dyspnoea with care. This was not a safety study,
and it was not powered to detect significant side effects.
The data imply that side effects were minimal. Neither
respiratory depression nor severe sedation was identi-
fied. All participants who withdrew because of
morphine encountered vomiting or sedation, which
may be transient or treatable. Constipation was the
only notable and common side effect. Review of the
daily constipation scores showed that the constipation
started to improve by the fourth day of the morphine
period; early intervention could have an impact. An
important consideration is that most patients who
would be considering this treatment do not have any
other options and are otherwise severely distressed
and limited by their breathlessness. Hence, although
the risk of constipation and other side effects is real,
this may be an appropriate treatment for many
patients, provided that the patient and doctor monitor
for clinical benefit and side effects together.
Table 4 Effect of morphine versus placebo on constipation at the end of the four day
treatment period. Variable is measured on a categorical scale; response items are
collapsed into dichotomous functional groupings. Values are numbers
Constipation on placebo
Constipation on morphine None or mild Moderate or severe Totals
None or mild 26 1 27
Moderate or severe 9 1 10
Totals 35 2 37
P=0.021
Table 3 Effect of morphine versus placebo on sleep at the end
of the four day treatment period. Variable is measured on a
categorical scale; response items are collapsed into dichotomous
functional groupings. Values are numbers
Sleep disturbed by
breathlessness on
morphine
Sleep disturbed by breathlessness on placebo
Yes No Totals
Yes 4 1 5
No 8 25 33
Totals 12 26 38
P=0.039
Days
%
 o
f p
ar
tic
ip
an
ts
1 2 3 4 1 2 3 4 1 2 3 4
Morphine
Placebo
(order = placebo
then morphine)
Placebo
(order = morphine
then placebo)
0
20
40
60
80
100
Severe Moderate Mild None
Frequency of constipation throughout the treatment periods, by
treatment intervention. Data are presented as the percentage of
participants indicating each categorical response on each day of the
treatment period. Placebo responses are divided between participants
who received placebo during the first period (first placebo, then
morphine) or the second period (first morphine, then placebo) to
show carry over effects
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Limitations
The study design has several limitations. Firstly, there
was no washout (no treatment) period. Figure 2 shows
the persistence of the side effects of morphine into the
early part of the placebo period. We recognised these
risks a priori. The challenge was to develop a short
protocol that would be acceptable and ethical for a
group of very ill patients who did not have any other
medical options. Although a parallel trial would have
addressed this concern, it would have doubled
numbers in a clinical population for which others have
had difficulty recruiting. Instead we elected a crossover
trial with an analysis plan that concentrated on the end
of the treatment period only.14 We planned that
sequence and period analyses would precede any
analysis of treatment; fortunately, neither sequence nor
period effects were identified.
Secondly, there was no blinding for constipation.
To accommodate this, the only investigator aware of
the constipation was the study nurse (AM), who was
not involved in the analysis. Thirdly, the morphine
dose chosen was 20 mg daily. Some clinicians may
regard this as a relatively high dose in patients who had
not been treated with opioids before. As the study was
being designed it was the lowest once daily, sustained
release formulation available. Subsequent dose rang-
ing studies are needed.
Fourthly, the reduced evening dyspnoea scores and
improved sleep may have been related to changes
made by the participant, such as increased use of oxy-
gen during the day or continuous positive airway pres-
sure at night. Such potential confounders should have
been equally distributed between the groups through
randomisation. Finally, the clinical significance of a
7-10 mm change in the visual analogue scale may be
questioned. We are not aware of any studies that corre-
late direct clinical meaning with specific changes of
distance in the dyspnoea scale. None the less, in a
population of patients in whom pharmacological
treatment is not an option, the opportunity for a 5-10%
improvement in a disabling symptom is welcome.
This study shows that rigorous randomised
controlled trials can be performed in this population.
Key factors were a short study period, simple bedside
evaluation, collaboration across disciplines, one identi-
fied recruitment nurse, once daily dosing, and an
evolving clinical culture that seeks evidence based
approaches to care. Future directions include an effec-
tiveness study that is adequately powered to evaluate
safety. Such a study may well show that, with close
monitoring, patients could continue taking opioids
while tolerance develops to the nausea and sedation.
Dose ranging studies in opioid tolerant and naive
participants are also planned.
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Side effects were minimal and no evidence of
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4 Morphine 4 Chest pain and nausea Nausea may be caused by morphine
5 Morphine 6 Rapid atrial fibrillation, admitted to
intensive care unit
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9 Placebo 5 Increased dyspnoea with treatment change Likely to be caused by change from
morphine to placebo; refused to continue
with crossover
10 Placebo 6 Constipation and sedation Likely carry over effects of morphine
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